MELİH ENGİN ERKAN, MUHAMMET AŞIK, Taner UÇGUN, Nilgün YILDIZ, AYŞE YILMAZ, Yusuf ASLANTAŞ, Serkan BULUR, HURİ TİLLA İLÇE, Mustafa YILDIRIM, Ramazan MEMİŞOĞULLARI, AHMET SEMİH DOĞAN

Asymmetric dimethylarginine is not a good predictor of ischemiausing myocardial perfusion scintigraphy

Background/aim: Asymmetric dimethylarginine (ADMA) plays role in the pathogenesis of coronary artery disease and related mortality and morbidity through a number of mechanisms. We hypothesized that plasma ADMA levels would be increased in the presence of reversible ischemia as measured by GATED single photon emission computed tomography (SPECT) myocardial perfusion scintigraphy (MPS). Materials and methods: Fasting i.v. blood samples were drawn before testing. All patients underwent 99mTc-sestamibi GATED SPECT MPS with a one-day stress-rest protocol; the images were visually analyzed. Post-stress GATED parameters, including ejection fraction, end systolic and end diastolic volumes, and automatic stress defect scores, were recorded. Results: The plasma ADMA levels were higher in the ischemic group than in the non-ischemic group (0.46 ± 0.19 vs. 0.40 ± 0.15; P = 0.016). Plasma ADMA levels (odds ratio [OR] = 13.5; 95% confidence interval [CI] = 1.7-109.01; P = 0.015) and sex (OR = 2.49, 95% CI = 1.18-5.26; P = 0.017) were independent predictors of ischemia. There was no linear correlation between plasma ADMA levels and both the GATED SPECT and stress test parameters. Conclusion: Our data support the hypothesis that increased baseline ADMA levels are independently related with the presence of reversible ischemia.

Anahtar Kelimeler:

Asymmetric dimethylarginine, single photon emission computed tomography, ischemia

Asymmetric dimethylarginine is not a good predictor of ischemiausing myocardial perfusion scintigraphy

Keywords:

Asymmetric dimethylarginine, single photon emission computed tomography, ischemia,

PDF

___

1. Derkacz A, Protasiewicz M, Poręba R, Doroszko A, Poręba M, Antonowicz-Juchniewicz J , Andrzejak R, Szuba A. Plasma asymmetric dimethylarginine predicts restenosis after coronary angioplasty. Arch Med Sci 2011; 7: 444–448.
2. Lu TM, Chung MY, Lin MW, Hsu CP, Lin SJ. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography. Int J Cardiol 2011; 153: 135–140.
3. Sen N, Ozlu MF, Akgul EO, Kanat S, Cayci T, Turak O, Yaman H, Sokmen E, Ozcan F, Maden O et al. Elevated plasma asymmetric dimethylarginine level in acute myocardial infarction patients as a predictor of poor prognosis and angiographic impaired reperfusion. Atherosclerosis 2011; 219: 304–310.
4. Sibal L, Agarwal SC, Home PD, Boger RH. The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr Cardiol Rev 2010; 6: 82–90.
5. Coluzzi G, Santucci E, Marzo F, Andreotti F. Asymmetric dimethylarginine and impaired cardiovascular healing. J Thromb Thrombolysis 2009; 27: 168–171.
6. Gratz S, Kaiser W, Höffken H. Diagnostic imaging in patients with coronary artery disease: the nuclear medicine physicians’ view. Deut Med Wochenschr 2011; 136: 2094–2099 (in German with abstract in English).
7. Adamson K. Principles of myocardial SPECT imaging. In: Movahed A, Gnanasegaran G, Buscompe J, Hall M, editors. Integrating Cardiology for Nuclear Medicine Physicians. Berlin, Germany: Springer-Verlag; 2009. pp. 191–210.
8. Iskander P, Iskandrian AE. Risk assessment using singlephoton emission computed tomographic technetium-99m sestamibi imaging. J Am Coll Cardiol 1998; 32: 57–62.
9. Ilic MD, Ilic S, Lazarevic G, Kocic G, Pavlovic R, Stefanovic V. Impact of reversible myocardial ischemia on nitric oxide and asymmetric dimethylarginine production in patients with high risk for coronary heart disease. Med Sci Monit 2010; 16: 397– 404.
10. Djordjević BV, Pavlović R, Ćosić V, Deljanin-Ilić M, Ristić T, Krstić N, Jevtović-Stoimenov T. High clinical accuracy of asymmetric dimethylarginine and symmetric dimethylarginine in patients with ischemic heart disease. Amino Acids 2012; 43: 2293–2300.
11. Cao Y, Yang K, Zhang Z, Ouyang M, Xiao L. Correlation between plasma asymmetric dimethylarginine and different types of coronary heart disease. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2010; 35: 301–306.
12. Krempl TK, Maas R, Sydow K, Meinertz T, Böger RH, Kähler J. Elevation of asymmetric dimethylarginine in patients with unstable angina and recurrent cardiovascular events. Eur Heart J 2005; 26: 1846–1851.
13. Valkonen VP, Päivä H, Salonen JT, Lakka TA, Lehtimäki T, Laakso J, Laaksonen R. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2000; 358: 2127–2128.
14. Lu TM, Ding YA, Charng MJ, Lin SJ. Asymmetrical dimethylarginine: a novel risk factor for coronary artery disease. Clin Cardiol 2003; 26: 458–464.
15. Lu TM, Chung MY, Lin MW, Hsu CP, Lin SJ. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography. Int J Cardiol 2011; 153: 135–140.
16. Song Y, Qu XF, Yu YW, Luan TZ, Li JJ, Guo H, Yu Y. Relationship between plasma asymmetrical dimethyl arginine and coronary artery disease. Zhonghua Yi Xue Za Zhi 2007; 87: 1527–1530.